MDWD vs KROS vs BEAM vs ARWR

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -16. 1% for MediWound Ltd. (MDWD). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate MediWound Ltd. (MDWD) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arrowhead Pharmaceuticals, Inc.

(ARWR) delivered a total return of +17. 4%, compared to -78. 1% for Keros Therapeutics, Inc. (KROS). Over 10 years, the gap is even starker: ARWR returned +1162% versus MDWD's -69. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Keros Therapeutics, Inc.

(KROS) is the lower-risk stock at 1. 00β versus Beam Therapeutics Inc. 's 2. 08β — meaning BEAM is approximately 108% more volatile than KROS relative to the S&P 500. On balance sheet safety, Keros Therapeutics, Inc. (KROS) carries a lower debt/equity ratio of 6% versus 73% for Arrowhead Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -16. 1% for MediWound Ltd. (MDWD). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to 30. 7% for MediWound Ltd.. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Keros Therapeutics, Inc.

(KROS) is the more profitable company, earning 35. 7% net margin versus -140. 8% for MediWound Ltd. — meaning it keeps 35. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KROS leads at 28. 9% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1162% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARWR: +1162%, BEAM: +72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MDWD is a small-cap quality compounder stock; KROS is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.